Wealthy Western countries which are buying up the other highly effective vaccines, are going to push these off on the poor countries, aren't they?
Pharmaceutical company AstraZeneca has released additional data that it said confirms the efficacy of its Covid-19 vaccine after questions about interim clinical trial results were raised in the US by an independent agency. But the additional data suggests the vaccine is slightly – but not significantly – less effective than the interim results suggested.
Interim results released by AstraZeneca on Monday from the phase-3 clinical trial of more than 32,000 people found the vaccine was 79% effective against symptomatic disease and 100% effective against severe disease and death. But soon after the results were published, the Data and Safety Monitoring Board in the US said it was concerned AstraZeneca may have provided “outdated information” from the trial, which gave “an incomplete view” of the results.
Guardian
Well, guess what? Suddenly AstraZeneca found additional data. Like those additional votes Trump complained about.
This means there is a 95% chance that the true efficacy of the vaccine is between 68% to 82%, making it similar to other vaccines including Pfizer’s.
[...]
“We heard very positive news almost a week ago that the European Medical Authority’s safety committee concluded that the vaccine was not associated with an increase in the overall risk of blood clots and therefore the benefits of receiving the vaccine continue to outweigh the risk of side effects.”
Uh-huh. It's good enough for the poor countries.
No comments:
Post a Comment